Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors’ Liability Premiums
  • Florida’s KidCare

TRENDING TOPICS:

  • Community Health Workers
  • Rural Health Payout
  • Measles Outbreaks
  • Doctors' Liability Premiums
  • Florida’s KidCare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Feb 15 2024

Full Issue

Eicos Science Injection Is First FDA-Approved Frostbite Treatment

The drug will be sold under the brand name Aurlumyn and is expected to be available in the spring, though pricing is not yet known. Meanwhile, prescriptions for the first pill to treat postpartum depression are said to be "off to a promising start" after its launch.

The U.S. Food and Drug Administration on Wednesday approved Eicos Sciences' injection, making it the first-ever treatment to treat severe frostbite in adults. The treatment, which will help reduce the risk of amputation, will be sold under the brand name Aurlumyn and is expected to be available in Spring 2024, although its pricing has not yet been determined, the company said in an e-mailed statement. (2/14)

In other pharmaceutical developments —

At least 120 prescriptions were written for the first pill treating postpartum depression in the days following its launch, drugmaker Sage Therapeutics disclosed in its year-end earnings report on Wednesday. Postpartum depression affects an estimated 500,000 people each year. But with a launch price of $15,900 for the drug Zurzuvae, analysts had expressed uncertainty about its potential market and how insurers may cover the treatment. (Reed, 2/15)

A new Centers for Disease Control and Prevention (CDC) report today notes that 38.6% of children age 9 to 17 had received at least one dose of the human papillomavirus (HPV) vaccine in 2022, with rates rising with age from 7% in the youngest kids to 57% in the oldest. HPV vaccination has been recommended in the United States since 2006 for girls and 2011 for boys. The multiple-dose vaccine, targeted to be initiated for children ages 11 to 12 years, may be started as young as age 9 and prevents against the most common cancer-causing HPV strains. (Soucheray, 2/14)

A new program called SHIP Trial Network, led by the National Cancer Institute (NCI), is exploring testing for human papillomavirus (HPV) via self-collection to prevent cervical cancer, according to a press release.The Last Mile Initiative, announced at the White House Cervical Cancer Forum on Jan. 25 by NCI's director Dr. Kimryn Rathmell, will gather data on a self-collection method for HPV. (Stabile, 2/15)

President Vladimir Putin said on Wednesday that Russian scientists were close to creating vaccines for cancer that could soon be available to patients. Putin said in televised comments that "we have come very close to the creation of so-called cancer vaccines and immunomodulatory drugs of a new generation". Putin did not specify which types of cancer the proposed vaccines would target, nor how. (2/14)

The emergency global stockpile of cholera vaccines is empty with all available doses for this month already allocated to countries battling major outbreaks, two United Nations agencies told Reuters. The rest of this year will see a predicted shortfall of at least 50 million doses between demand and supply, a UNICEF official added, as cases continue to surge worldwide. (Rigby and Dickie, 2/14)

Catalent has reduced its headcount by about 300 employees as part of its ongoing restructuring plans, the company disclosed in a regulatory filing on Wednesday. The contract drug manufacturer first adopted plans to reduce costs and consolidate facilities last June and extended the efforts during the second-quarter with reported job-cuts in its Biologics and Pharma and Consumer Health segments. (2/14)

On smoking and vaping —

A new trove of internal emails and other documents from the e-cigarette maker Juul reveals the company’s extensive behind-the-scenes efforts to promote its interests in Washington — a rare insight into the otherwise opaque methods corporations use to influence the government. (Florko, 2/15)

Public health messages have told us for decades that if you smoke, you should quit. And if you don’t smoke, don’t start. But a new study suggests smoking may be even worse than we thought. (Cooney, 2/14)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ